Kiniksa reports preliminary Q4 ARCALYST net product revenue $121.9M

ARCALYST 2025 net product revenue expected to be $560 – $580 million. “ARCALYST uptake in recurrent pericarditis continues to grow. As of the end of 2024, approximately 13% of the multiple-recurrence target population was actively on ARCALYST therapy, driving net product revenue to $416.4 million, representing 79% year-over-year growth. Importantly, there is still substantial opportunity ahead for Kiniksa (KNSA) to drive further ARCALYST revenue as we continue executing on our commercial strategy,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “We are also advancing our clinical portfolio as we work to bring new life-changing therapies to patients with unmet medical needs. Lastly, our robust financial profile provides the ability to pursue additional value-creating opportunities.”